Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy
The Oncologist · 05.11.2026 · 31 (12)
DOI: 10.1093/oncolo/oyag434 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 04.11.2026. Verfasst von Yi-Shao Justus Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc, Thousand Oaks, CA 91320, United States. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc..
Abstract (Originalsprache)
Background
Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited. Patients and Methods This descriptive retrospective observational study used the US-based, electronic health record-derived deidentified Flatiron Health Research Database (January 2013-December 2024). Adults with pathologically confirmed ES-SCLC at initial diagnosis initiating 1L therapy were included. Patients were categorized by 1L regimen: PE plus a PD-L1 inhibitor (chemo-immunotherapy), PE alone, or other regimens. Maintenance was defined as at least 2 consecutive doses of post-induction PD-L1 inhibitor monotherapy. Real-world overall survival (rwOS) and progression-free survival (rwPFS) were estimated using the Kaplan-Meier method.
Results
Among 5863 1L patients, 2157 (36.8%) received chemo-immunotherapy, of whom ∼60% (1284/2157) received maintenance (atezolizumab, 85.7%; durvalumab 14.3%); 3376 (57.6%) received PE, and 330 (5.6%) other regimens. Median rwOS and rwPFS from 1L initiation were 8.1 months (95% CI, 8.0-8.3) and 5.1 months (95% CI, 5.0-5.2), respectively. From 1L initiation, patients who subsequently met the maintenance definition had median rwOS of 12.2 months. From maintenance initiation, median rwOS was 8.7 months (95% CI, 8.0-9.8) with atezolizumab and 9.3 months (95% CI, 8.0-11.5) with durvalumab.
Conclusion
In this large US real-world cohort, survival outcomes in 1L ES-SCLC patients were poor and appeared broadly comparable between atezolizumab and durvalumab. Only ∼60% of patients receiving chemo-immunotherapy subsequently received maintenance in routine clinical practice, underscoring substantial attrition before maintenance initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amgen Inc, Thousand Oaks, CA 91320, United States.
- Department of Hematology & Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19140, United States.
- Brown University School of Medicine-Rhode Island Hospital, Providence, RI 02903, United States.
- Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, United States.
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, United States.
- Sarah Cannon Research Institute, Nashville, TN 37203, United States.
ORCID-Profile: Yi-Shao Justus Liu, Parth A Desai, Christine L Hann, Melissa L Johnson, Jessie Wang, Xerxes Pundole
Förderung
- Amgen Inc.
Zitieren
APA
Liu, Y. J., Desai, P. A., Khurshid, H., Chiang, A. C., Hann, C. L., Johnson, M. L., Anderson, E. S., Najdi, R., Wang, J., & Pundole, X. (2026). Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy. The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag434
Vancouver
Liu YJ, Desai PA, Khurshid H, Chiang AC, Hann CL, Johnson ML, et al. Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy. The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag434
BibTeX
@article{Liu2026,
author = {Liu, Yi-Shao Justus and Desai, Parth A and Khurshid, Humera and Chiang, Anne C and Hann, Christine L and Johnson, Melissa L and Anderson, Erik S and Najdi, Rani and Wang, Jessie and Pundole, Xerxes},
title = {Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {12},
doi = {10.1093/oncolo/oyag434}
}
EUVIMED